Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study

Janjigian, Y. Y., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J-P., Weber, P. E. Yanez, Wyrwicz, L. S., Shen, L., Ostapenko, Y. V., Bilici, M., Chung, H. C., Shitara, K., Qin, S., Van Cutsem, E., Tabernero, J., Li, K., Shih, C-S., Bhagia, P., Rha, S. Y.